Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Exchange: NASDAQ GM
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Amicus Therapeutics Inc

+ Add to Watchlist

FOLD:US

3.4000 USD 0.0200 0.58%

As of 20:10:00 ET on 05/24/2013.

Company Profile for Amicus Therapeutics Inc (FOLD)

Amicus Therapeutics, Inc. is a biopharmaceutical company that develops orally-administered, small molecule drugs to treat human genetic diseases. The drugs, called pharmacological chaperones, are being developed to treat Fabray, Gaucher, and Pompe disease.

Contact Information

Amicus Therapeutics Inc

6 Cedar Brook Drive
Cranbury, NJ 08512
United States
Phone: 1-609-662-2000

Key Executives for Amicus Therapeutics Inc (FOLD)

John F CrowleyChairman/CEOWilliam D Baird III "Chip"Chief Financial Officer
David J LockhartChief Scientific OfficerBradley L CampbellChief Business Officer
Peter M MacalusoVP/Secretary/CounselJohn R KirkVP:Regulatory Affairs
Ken ValenzanoVP:PharmacologyKenneth W PeistVP:Intellectual Property
Enrique DiloneVP:Technical OperationsDaphne QuimiController

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil